title: Medical management of angle closure glaucoma.
abstract: Management of angle closure glaucoma requires an understanding of the underlying pathophysiologic mechanisms. Treatment is aimed at eliminating pupillary block and other causes of angle closure, re-opening the angle, and preventing further damage to the optic nerve by lowering intraocular pressure. Medical therapy plays an important role in the successful management of this condition. This article describes commonly used pharmacologic agents, as well as newer classes of drugs such as topical carbonic anhydrase inhibitors, prostaglandin analogues and selective alpha2- adrenergic agonists. Use of these drugs in several clinically distinct angle closure syndromes and modes of presentation are discussed.
authors.affiliation: Singapore National Eye Centre, Singapore.
authors.forename: Sek-Tien
authors.initials: ST
authors.lastname: Hoh
authors.forename: Tin
authors.initials: T
authors.lastname: Aung
authors.forename: Paul T K
authors.initials: PT
authors.lastname: Chew
mesh_terms: D000322:Adrenergic Agonists / Q000009:adverse effects / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy*; D006801:Humans; D008916:Miotics / Q000009:adverse effects / Q000627:therapeutic use; D011453:Prostaglandins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000322:Adrenergic Agonists; D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D008916:Miotics; D011453:Prostaglandins